×

Tyrosine kinase inhibitors

  • US 8,946,241 B2
  • Filed: 02/20/2014
  • Issued: 02/03/2015
  • Est. Priority Date: 04/09/2013
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating inflammatory bowel disease, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, Sjogren'"'"'s syndrome, multiple sclerosis, ankylosing spondylitis, idiopathic thrombocytopenic purpura, scleroderma, Wegener'"'"'s granulomatosis, psoriasis, asthma, colitis, conjunctivitis, dermatitis, uveitis, eczema, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, non-Hodgkin lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt'"'"'s lymphoma/leukemia, or lymphomatoid granulomatosis which method comprises administering to the patient in need thereof, a pharmaceutical composition comprising a (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers thereof, or a pharmaceutically acceptable salt of any of the foregoing compounds, and a pharmaceutically acceptable excipient, wherein the compound is:

  • 2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile having the structure;

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×